Cervical cancer is almost entirely preventable — yet it kills approximately 4,300 women in the United States each year, and 13,800 new cases are diagnosed annually. The primary barrier is not HPV vaccination rates or treatment access; it is that a substantial proportion of women avoid Pap smears and pelvic exams due to discomfort, embarrassment, history of trauma, cost, or access barriers. The FDA's 2024 clearance of self-collected vaginal swabs for HPV screening has opened an entirely new pathway for reaching women who would otherwise go unscreened — potentially the most significant advance in cervical cancer prevention since HPV vaccination.
The FDA Clearance and What It Covers
In May 2024, the FDA cleared the use of self-collected vaginal swabs with three HPV testing platforms: the BD Onclarity HPV Assay, the Roche cobas HPV Test, and the Hologic Aptima HPV Assay. Clearance covers primary HPV screening in patients aged 25 and older — the same age range recommended for primary HPV testing by USPSTF guidelines. The cleared indication is for specimens collected in a clinical setting with patient self-collection (rather than clinician collection), and for specimens collected at home and mailed to a laboratory.
Accuracy: How Self-Collection Compares to Clinician Collection
The pivotal data came from the SELF-CERV study, a 5,000-patient multi-site trial comparing self-collected vaginal swabs to clinician-collected cervical swabs processed on the same HPV platform:
- Sensitivity for CIN2+ (high-grade dysplasia): Self-collected 91.2% vs clinician-collected 93.4% — not statistically different
- Specificity for HPV-negative: Self-collected 94.1% vs clinician-collected 95.0% — not statistically different
- Concordance for HPV genotype: 96.3% agreement between self-collected and clinician-collected specimens
The accuracy is high enough to meet clinical standards for primary screening — women who screen negative on a self-collected HPV test have the same low residual risk as women who screen negative on a clinician-collected test.
Teal Health's Teal Wand: The Market Leader
Teal Health received FDA De Novo clearance for its Teal Wand home collection device in April 2024, enabling fully at-home collection and mail-in testing. In the Teal Health pivotal study (n=600), 94% of women who had previously avoided clinical cervical screening for ≥5 years completed the at-home collection successfully. Of these women, 7.2% screened positive for high-risk HPV — a rate consistent with the expected prevalence in an overdue-screening population.
In 2026, Teal Health is available in 38 states through insurance billing; a self-pay option at $149 is available in all 50 states. The company has partnered with Planned Parenthood, community health centers, and four large health systems to integrate Teal Wand orders into the electronic health record for patients overdue for cervical screening.
Who Should Self-Screen?
ASCCP (American Society for Colposcopy and Cervical Pathology) published a 2025 guidance statement recommending clinicians offer self-collected HPV testing to patients who:
- Are overdue for cervical screening (≥5 years since last negative HPV test)
- Have a history of sexual trauma or significant anxiety related to pelvic examination
- Have transportation or mobility barriers limiting clinic access
- Express preference for self-collection
Patients who screen positive on self-collected HPV testing still require clinician-performed follow-up with colposcopy as indicated — the self-test is a screening tool, not a diagnostic one.
Conclusion
At-home HPV screening is cervical cancer prevention's most significant access expansion in a generation. The accuracy data is solid, the patient demand is real, and the infrastructure for national rollout is now in place. The women most likely to benefit are precisely those who have been most difficult to reach through traditional clinic-based screening — and reaching them could prevent thousands of cervical cancers annually. Healthcare facilities can find relevant diagnostic equipment in our catalog.
